Please enter a keyword
EN
CN
JP
About Sungen
Company Profile
Milestones
Social Responsibilities
Contact Us
Join Us
Research & Development
Research Platforms
Research Centers
Research Institutes
New Raw Materials of Pharmaceutical
Innovative Manufacture
Lighthouse Factory
Biofabrication
Key Control System
Quality Management
Authoritative Certification
Clinical Research
Real-World Study
Research Fund
Research Papers Published
Brand ANI
Products
Recombinant Hirudin by Genetic Engineering with Anticoagulant Drug
Project Introduction
R&D Process
Patent Certification
     Leech is a traditional special medicinal aquatic animal in China, which is recorded in Shennong Ben Cao Jing, Materia Medica and modern editions of Chinese Pharmacopoeia, and has the efficacy of breaking blood, expelling blood stasis and promoting menstruation by concocting medicine. Hirudin is a component extracted from leech and its salivary gland, which has good anticoagulant and antithrombotic effects, and has good preventive and therapeutic effects on various thrombotic diseases such as venous thrombosis, disseminated intravascular coagulation, cerebral thrombosis, thrombophlebitis and coronary thrombosis. Hirudin is the most effective natural specific inhibitor of thrombin found to date.

   Most of the hirudin product on the market are made by grounding leeches into powder, which may contain impurities, heavy metals and pesticide residues in excess of the standard. Long-term use of such products can cause certain effects on the body`s liver and kidneys and other organs.

     Sungen utilize genetic engineering fermentation to produce recombinant hirudin, which has the characteristics of high safety, high stability, high activity and high yield. The project has become one of the third national "five-year plan" promotion projects, and Sungen has the exclusive invention patent technology and right of global pricing.

Year 1991    

Sungen started the R&D of recombinant hirudin.


Year 2003    

Sungen signed a cooperation agreement with the Academy of Life Sciences of Peking University on "Genetically engineered recombinant hirudin for anticoagulant drug" to produce recombinant hirudin by genetic engineering fermentation.


Year 2004    

Sungen, together with the School of Life Sciences of Peking University and the Department of Medicine of Peking University, and invited famous experts in the domestic cardiovascular field to hold the "Clinical Indication Validation Meeting of Recombinant Hirudin" in Beijing to discuss the further in-depth research of the recombinant hirudin project.


Year 2015    

Sungen invited experts from many top research institutes such as Peking University College of Life Sciences, China Medical University, Shenyang Pharmaceutical University, etc. to hold the "Seminar on the Application of Hirudin Blood Vessel Harvesting Coating and Oral Nano Agent" in Beijing.


Year 2019    

Sungen launched the product of hirudin enteric tablets base on R&D of recombinant hirudin.

Patent No. ：ZL03109244.6
Sungen obtained exclusive patent technology transfer of the recombinant hirudin primary structure, HV2 mutant (Asn→Lys47) gene.

About Us
Research & Development
Innovative Manufacture
Clinical Research
Brand ANI
Products
Join Us
COPYRIGHT © 2019 Guangdong Sungen Bioscience Co., Ltd.
Guangdong ICP 15051377-4
Powered by Fractal-technology
The basic information